ProfessionalsChristopher Gonnella
Tel: +1-212-373-2216
Fax: +1-347-402-7696
cgonnella@paulweiss.com
1285 Avenue of the Americas
New York,
NY
10019-6064
Fax: +1-347-402-7696
Partner elect in the firm's Executive Compensation Group, Christopher Gonnella advises clients on a wide range of executive compensation matters. His transactional practice involves advising on mergers and acquisitions, divestitures, spin offs, joint ventures and private equity transactions. He also regularly counsels both corporate and individual clients on the design, negotiation and implementation of employment agreements and incentive compensation programs. Additionally, Christopher handles securities law compliance matters relating to executive compensation, including new and evolving regulatory matters, such as clawback rules, pay vs. performance disclosure and related matters.
EXPERIENCE
Christopher’s notable transactions include representing:
- Newcrest in its $28.8 billion acquisition by Newmont
- FS Investments in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm
- Amazon in its $8.45 billion acquisition of MGM
- Global Blood Therapeutics in its $5.4 billion sale to Pfizer
- Altra Industrial Motion in its $5 billion sale to Regal Rexnord
- Mylan in its $50 billion combination with Upjohn, a division of Pfizer, to form Viatris
- Pinnacle Foods in its $10.9 billion acquisition by Conagra Brands
- British American Tobacco in its $97 billion merger with Reynolds American
- Viatris in its divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the pending divestitures of its Over the Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses
- IBM in multiple transactions, including the sale of its healthcare and data analytics assets, part of the Watson Health business, to Francisco Partners